Cancer Pathogenesis and Therapy: review time and acceptance speed
ISSN 2949-7132 · Elsevier BV · Medicine
Half of the articles Cancer Pathogenesis and Therapy accepted in 2023 were accepted within 92 days of submission (n = 50); the middle half took 67–111 days.
Accepted articles only · dates deposited by the publisher in PubMed · data as of Sep 15, 2026
How long does Cancer Pathogenesis and Therapy take to accept a paper?
| Year | Articles (n) | 25th pct | Median | 75th pct | 90th pct | Accepted <14 days | Have a revised date |
|---|---|---|---|---|---|---|---|
| 2023 | 50 | 67 | 92 | 111 | — | 2.0% | 100% |
- 2026: not shown yet — a year is reported once late-indexed articles have arrived (at least 367 days after it ends).
- 2025: not shown yet — a year is reported once late-indexed articles have arrived (at least 367 days after it ends).
Distribution in 2023
Show as a table
| Days | Articles | Share |
|---|---|---|
| 0–29 | 1 | 2.0% |
| 30–59 | 7 | 14.0% |
| 60–89 | 16 | 32.0% |
| 90–119 | 16 | 32.0% |
| 120–149 | 4 | 8.0% |
| 150–179 | 3 | 6.0% |
| 180–209 | 1 | 2.0% |
| 210–239 | 1 | 2.0% |
| 240–269 | 0 | 0.0% |
| 270–299 | 1 | 2.0% |
| 300–329 | 0 | 0.0% |
| 330–359 | 0 | 0.0% |
| 360+ | 0 | 0.0% |
From acceptance to online publication
Not enough articles with both an acceptance date and an online publication date to measure the time to online publication.
Read these numbers carefully
- These times describe articles the journal accepted. Rejected manuscripts never appear in public data, so they cannot tell you how long a rejection takes.
- Dates are the ones the publisher deposited with PubMed. Some publishers record the date a revised manuscript arrived as the submission date, which makes review look faster.
- Invited articles and special issues can move faster than regular submissions.
Open access status and publishing fees
Open access (listed in DOAJ). Listed APC: $2,700 (DOAJ).
No institutional payments for this journal are recorded in OpenAPC.
Many journals waive or reduce fees for authors from eligible countries or institutions with publishing agreements — check with the journal and your library.
Integrity and indexing signals
Facts from public records, shown without judgement. See the methodology for why each can be worth a closer look.
| Listed in DOAJ | Yes (DOAJ record) |
|---|---|
| Articles indexed for MEDLINE in 2023 | None found (the journal may be in PubMed through PubMed Central instead) |
| Retractions | 0 retracted articles among 133 added to PubMed in 2021–2025, per the Retraction Watch Database. |
| Accepted within 14 days of submission | 2.0% of 2023 articles |
| Publication volume | 3 articles added to PubMed in 2023. |
Topics and scope
- Cancer Immunotherapy and Biomarkers (11% of indexed topics)
- Diverse Scientific and Economic Studies (9% of indexed topics)
- Lung Cancer Treatments and Mutations (7% of indexed topics)
- Ferroelectric and Negative Capacitance Devices (6% of indexed topics)
- Big Data and Digital Economy (6% of indexed topics)
- Ferroptosis and cancer prognosis (4% of indexed topics)
Similar journals — faster or cheaper, side by side
Journals publishing on the most similar topics (OpenAlex), ordered by similarity. Only 2023 figures are compared with the 2023 median of Cancer Pathogenesis and Therapy, 92 days.
| Paid APC median | DOAJ | MEDLINE | |||
|---|---|---|---|---|---|
| Cancer Research Communications | 146 (2023, n = 227) | $2,550 | $2,503 (12 payments) | Yes | Yes |
| Translational Oncology | 94 (2023, n = 256) | $3,880 | — | Yes | No |
| Translational Cancer Research | 136 (2023, n = 295) | — | — | No | No |
| Cancer Innovation | 74 (2023, n = 55) | $2,700 | — | Yes | No |
| Biomarker Research | 76 (2023, n = 83) | $4,090 | $3,296 (7 payments) | Yes | No |
| Critical Reviews in Oncology/Hematology | 122 (2023, n = 203) | ≈$4,190 | — | No | Yes |
| Trends in cancer | 50 (2023, n = 100) | ≈$7,030 | — | No | Yes |
| Frontiers in Oncology | 85 (2023, n = 4,263) | ≈$3,850 | $3,497 (212 payments) | Yes | No |
No journals match these filters.
Frequently asked questions
How long does Cancer Pathogenesis and Therapy take to accept a paper?
Half of the articles Cancer Pathogenesis and Therapy accepted in 2023 were accepted within 92 days of submission (n = 50); the middle half took 67–111 days. Based on dates in PubMed for accepted articles only.
Does Cancer Pathogenesis and Therapy charge an article processing charge (APC)?
Listed APC: $2,700 (DOAJ).
Sources and method
Journal identity: ISSN-L 2949-7132; NLM ID 9918680788606676; OpenAlex record. Speed figures use 50 articles accepted in 2023 with valid dates; excluded records for that year: online date out of range 1.
Spotted a problem with this journal's data, or are you the publisher? Report a correction or email rafiq@gradsummit.com. Verified errors are corrected within five business days.
Get the free Journal Submission Go/No-Go Checklist
The pre-submission checks from Write and Publish a Scientific Paper: journal fit, formatting, cover letter and reviewer suggestions. We’ll email you the download link.
Data sources. Submission, acceptance and publication dates: Courtesy of the U.S. National Library of Medicine (PubMed, entries through Sep 15, 2026). NLM does not endorse Journal Clock, and these figures may not reflect the most current PubMed data. Journal fees and open-access listing: DOAJ (CC0, retrieved Sep 16, 2026). Fees paid by institutions: OpenAPC (Open Database License, retrieved Sep 16, 2026). Retractions: Retraction Watch Database via Crossref (retrieved Sep 16, 2026). Journal identifiers and topics: OpenAlex (CC0). Currency conversion: ECB reference rates (Sep 15, 2026). How these numbers are calculated · For organisations.